{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:58:32Z","timestamp":1768805912912,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007312","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00336","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T06:32:10Z","timestamp":1597732330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Infections in the Era of Targeted Therapies: Mapping the Road Ahead"],"prefix":"10.3389","volume":"7","author":[{"given":"Leonard H.","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiphaine","family":"Lenfant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/annrheumdis-2018-214024","article-title":"Tolerising cellular therapies: what is their promise for autoimmune disease?","volume":"78","author":"Mosanya","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules (I): anti-tumor necrosis factor-alpha agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens (II): CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens (I): CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules (II): agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.BAI-0019-2019","article-title":"Modeling infectious diseases in mice with a \u201cHumanized\u201d immune system","volume":"7","author":"Li","year":"2019","journal-title":"Microbiol Spectr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/art.11134","article-title":"Tuberculosis in the cytokine era: what rheumatologists need to know","volume":"48","author":"Hamilton","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10067-019-04866-x","article-title":"Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review","volume":"39","author":"Sartori","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13760.","article-title":"Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, evasion mechanisms","author":"Lewis","year":"2020","journal-title":"FEBS Lett."},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1385\/MB:18:2:135","article-title":"Animal models of inherited complement deficiency","volume":"18","author":"Linton","year":"2001","journal-title":"Mol Biotechnol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","article-title":"Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease","volume":"80","author":"Crew","year":"2020","journal-title":"J Infect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"iii48","DOI":"10.1136\/ard.2006.058404","article-title":"Natalizumab and progressive multifocal leucoencephalopathy","volume":"65","author":"Berger","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.12688\/f1000research.7071.1","article-title":"Progressive multifocal leukoencephalopathy","volume":"4","author":"Adang","year":"2015","journal-title":"F1000Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"1","author":"Berger","year":"2009","journal-title":"MAbs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.rdc.2016.09.009","article-title":"The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management","volume":"43","author":"Molloy","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune mediated diseases","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"B28","unstructured":"YimC\n          FDA, CDER: NDA 203214: Tofacitinib for RA: Cross Discipline Team Leader Review"},{"key":"B29","unstructured":"GlaserRS\n          S, HAI MT: NDA 211675 Upacitinib for RA Summary Review"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTT.S68949","article-title":"Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries","volume":"9","author":"Codreanu","year":"2015","journal-title":"Biologics Targets Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e000498","DOI":"10.1136\/rmdopen-2017-000498","article-title":"Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme","volume":"3","author":"Yamanaka","year":"2017","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","article-title":"Evaluation of the RABBIT Risk Score for serious infections","volume":"72","author":"Zink","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2017-211727","article-title":"Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study","volume":"77","author":"Curtis","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3899\/jrheum.150984","article-title":"A multifaceted intervention to improve influenza, pneumococcal, and herpes zoster vaccination among patients with rheumatoid arthritis","volume":"43","author":"Baker","year":"2016","journal-title":"J Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open."},{"key":"B40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","article-title":"Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement","volume":"20","author":"Wasan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","article-title":"Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake","volume":"9","author":"Malhi","year":"2015","journal-title":"J Crohns Colitis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3238\/arztebl.2011.0105","article-title":"Vaccination coverage in immunosuppressed patients: results of a regional health services research study","volume":"108","author":"Teich","year":"2011","journal-title":"Deutsches Arzteblatt Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0153848","DOI":"10.1371\/journal.pone.0153848","article-title":"Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: A Retrospective Cohort Study using data from the clinical practice research Datalink","volume":"11","author":"Costello","year":"2016","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jid.2018.09.012","article-title":"Influenza vaccination rates in adults with psoriasis compared to adults with other chronic diseases","volume":"139","author":"Noe","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.20524\/aog.2019.0351","article-title":"Improving immunization strategies in patients with inflammatory bowel disease","volume":"32","author":"Farshidpour","year":"2019","journal-title":"Ann Gastroenterol."},{"key":"B48","first-page":"161","article-title":"Understanding vaccination rates and attitudes among patients with rheumatoid arthritis","volume":"22","author":"Sandler","year":"2016","journal-title":"Am J Manag Care."},{"key":"B49","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.05.005","article-title":"Barriers to adult immunization","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.160179","article-title":"Improvement in herpes zoster vaccination in patients with rheumatoid arthritis: a quality improvement project","volume":"44","author":"Sheth","year":"2017","journal-title":"J Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3899\/jrheum.171377","article-title":"Improving the combination pneumococcal vaccination rate in systemic lupus erythematosus patients at an adult rheumatology practice","volume":"45","author":"Garg","year":"2018","journal-title":"J Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1016\/j.vaccine.2018.03.063","article-title":"Vaccine hesitancy around the globe: analysis of three years of WHO\/UNICEF joint reporting form data-2015-2017","volume":"36","author":"Lane","year":"2018","journal-title":"Vaccine."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T06:32:15Z","timestamp":1597732335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":52,"alternative-id":["10.3389\/fmed.2020.00336"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00336","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"article-number":"336"}}